Zika Virus Infection Clinical Trial
Official title:
Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome
Verified date | May 2019 |
Source | Universidade Federal de Pernambuco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Microcephaly associated with Congenital Syndrome of the Zika virus (SCVZ) was highlighted due to atypical structural and behavioral changes of the central nervous system. Such changes contribute to the appearance of functional impairments and difficulties of adaptation of the child to the necessary therapeutic follow-up. In this context, the search for adjuvant therapies that allow better management of these alterations has grown and, given its advantages, aquatic physiotherapy may be an auxiliary resource in the care of this population. The aquatic environment is capable of promoting a state of relaxation that, when associated with a kinesiotherapy protocol, is believed to have this potentiated effect. Thus, our objective will be to evaluate the efficacy of aquatic physiotherapy on the level of stress and muscle tone in children with microcephaly associated with SCVZ. A crossover, randomized, controlled and blind study will be carried out with children between 3 and 24 months of age, who will undergo two interventions: aquatic physiotherapy and water immersion. The evaluation of muscle tone will be performed through the Tardieu scale before and after the intervention; the physiological parameters (heart and respiratory rate, oxygen saturation and temperature) and the stress level will be evaluated before, immediately after and 30 minutes after the intervention. In addition, questionnaires will assess the child's behavioral state, level of irritation and sleep characteristics. For data normalization the Shapiro Wilk Test will be applied; the percentage values and relative frequency will be used for the descriptive analysis and for the numerical variables the values of mean and standard deviation or median and interquartile range. The paired T and ANOVA tests for repeated samples will be applied, which will analyze the intra-group time factor for the dependent variables of each individual. And for intergroup analysis, the variables may be submitted to the T-Test for independent or Mann-Whitney samples.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 30, 2018 |
Est. primary completion date | February 18, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Months to 24 Months |
Eligibility |
Inclusion Criteria: - Infants aged 3 to 24 months, diagnosed with microcephaly according to the recommendations of the Surveillance Protocol and response to the occurrence of microcephaly and / or CNS disorders, which considers head circumference less than or equal to 31.5 cm for term boys and 31.9 cm for full term girls. In cases of prematurity, the perimeter will be considered less than 2 or more standard deviations according to the Intergrowth table for gestational age and sex. Mothers should report presence of skin rash or confirmation of Zika virus infection during pregnancy. - Only children who are accompanied by a neurologist and assisted by physical therapy at least once a week will be included. Exclusion Criteria: - Children who are not taking anticonvulsant and / or antireflux medication when in the presence of seizures and gastroesophageal reflux, respectively; - Infants who have less than 3 months of botulinum toxin application; - Infants with osteomioarticular disorders, such as arthrogryposis, or other situations that impede the performance of evaluations and intervention; - Children who are already active in the aquatic environment (hot tub or hydrotherapy). |
Country | Name | City | State |
---|---|---|---|
Brazil | Universidade Federal de Pernambuco | Recife | Pernambuco |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal de Pernambuco |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change in Modified Tardieu Scale | assessment muscle tone at 5 degrees (0 = no resistance, 1 = slight resistance, no specific angle, 2 = moderate resistance with specific reaction angle, 3 = light clone, for less than 10 seconds, 4 = clusions for more than 10 seconds, 5 = immobile articulation). In addition to measuring the increase or decrease in the range of motion of each joint. | baseline and up 30 minutes | |
Secondary | change in heart rate | rate of the heart's beat, recorded as the number of beats per minute. | baseline and up 30 minutes | |
Secondary | change in respiratory frequency | The number of breaths per minute. | baseline and up 30 minutes | |
Secondary | change in oxygen saturation | the fraction of the hemoglobin molecules in a blood sample that are saturated with oxygen at a given partial pressure of oxygen. Normal saturation is 95% to 100%. | baseline and up 30 minutes | |
Secondary | change in body temperature | the degree of sensible heat or cold, expressed in terms of Celsius | baseline and up 30 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04697147 -
Zika and Neurodevelopment Among Infants in Grenada
|
N/A | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Completed |
NCT02952833 -
ZIKA Vaccine in Naive Subjects
|
Phase 1 | |
Terminated |
NCT03055585 -
Applying Wolbachia to Eliminate Dengue
|
N/A | |
Not yet recruiting |
NCT05589012 -
Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
|
||
Completed |
NCT02963909 -
A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
|
Phase 1 | |
Completed |
NCT03110770 -
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
|
Phase 2 | |
Recruiting |
NCT06334393 -
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
|
Phase 1 | |
Completed |
NCT03008122 -
Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area
|
Phase 1 | |
Terminated |
NCT03161444 -
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
|
N/A | |
Completed |
NCT04478656 -
Safety and Immunogenicity of BBV121
|
Phase 1 | |
Completed |
NCT03624946 -
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
|
Phase 1 | |
Completed |
NCT05041439 -
Adherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico
|
N/A | |
Recruiting |
NCT03255369 -
Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
|
||
Completed |
NCT03206541 -
Neurologic Manifestations of the Arbovirus Infection in Colombia
|
||
Completed |
NCT03425149 -
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
|
Phase 1 | |
Completed |
NCT04033068 -
Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
|
Phase 1 | |
Completed |
NCT03679728 -
Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection
|
||
Completed |
NCT03776903 -
Evaluation of the Clinical Performance of the ZIKV Detectâ„¢ 2.0 IgM Capture ELISA
|
||
Withdrawn |
NCT03204409 -
ZIKAlliance Natural History Study
|